Neuropathix, Inc.
NPTX · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $3,941 | $10,447 | $309,842 | $82,619 |
| - Cash | $16 | $22 | $121 | $307 |
| + Debt | $1,909 | $1,664 | $1,076 | $1,162 |
| Enterprise Value | $5,834 | $12,090 | $310,797 | $83,474 |
| Revenue | $183,477,000 | $0 | $126 | $174 |
| % Growth | – | -100% | -27.5% | – |
| Gross Profit | $183,477,000 | $0 | $126 | $174 |
| % Margin | 100% | – | 100% | 100% |
| EBITDA | -$2,920 | -$4,349 | -$1,349 | $41 |
| % Margin | -0% | – | -1,070.2% | 23.4% |
| Net Income | -$3,992 | -$5,570 | -$4,566 | $937 |
| % Margin | -0% | – | -3,622.9% | 538.7% |
| EPS Diluted | -0.046 | -0.075 | -0.064 | 0.014 |
| % Growth | 38.9% | -16.4% | -571.3% | – |
| Operating Cash Flow | -$890 | -$944 | -$1,894 | -$1,211 |
| Capital Expenditures | -$7 | $0 | -$42 | -$3 |
| Free Cash Flow | -$896 | -$944 | -$1,936 | -$1,214 |